Cross Country Healthcare Reports Steep Revenue Decline Amid Merger Fallout
Event summary
- Q4 2025 revenue dropped 24% YoY to $236.8M, with full-year revenue down 22% to $1.1B.
- Net loss widened to $82.9M in Q4 due to a $77.9M goodwill impairment charge and $29.6M tax valuation allowance.
- Adjusted EBITDA fell 56% YoY to $4.1M, with margins shrinking to 1.7% of revenue.
- Company repurchased 800K shares in Q4, reducing outstanding stock by 2.5%.
- Physician staffing revenue declined 20% YoY, while nurse and allied staffing fell 24%.
The big picture
Cross Country Healthcare's challenging year reflects broader pressures in the travel staffing market, compounded by the protracted merger process with Aya. The company is now focusing on leveraging its Intellify® platform and strategic investments to stabilize operations and return to profitability. With a strong balance sheet and no debt, management aims to exit 2026 at a $1B revenue run-rate and 4-5% profit margin, but execution risks remain high.
What we're watching
- Market Recovery Timing
- Whether the improving market conditions CEO Kevin Clark referenced will materialize and support revenue growth in 2026.
- Cost-Cutting Impact
- The effectiveness of the 21% US headcount reduction in driving sustainable cost savings through the India center of excellence.
- Technology Investment Returns
- How quickly Intellify® can drive meaningful efficiency gains and revenue growth as the core engine of future expansion.
Our editorial coverage: